Livzon Pharmaceutical Group Inc. (SHE:000513)

Market Cap	26.63B -6.7%
Revenue (ttm)	11.71B -0.3%
Net Income	1.96B -6.1%
EPS	2.20 -3.9%
Shares Out	887.91M
PE Ratio	14.82
Forward PE	13.70
Dividend	1.43 (4.39%)
Ex-Dividend Date	Jun 13, 2025

Volume	3,789,822
Average Volume	5,422,034
Open	33.10
Previous Close	32.54
Day's Range	32.50 - 33.10
52-Week Range	32.38 - 44.87
Beta	0.38
RSI	36.08
Earnings Date	Apr 23, 2026

About SHE:000513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neuro...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 8,878
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000513

Financial Performance

In 2025, SHE:000513's revenue was 12.02 billion, an increase of 1.76% compared to the previous year's 11.81 billion. Earnings were 2.02 billion, a decrease of -1.84%.